Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults

Clinical and Experimental Immunology

Volumn 116, Issue 3, 1999, Pages 468-473

  Jabs, Wolfram J ^a   Paulsen, M ^a   Wagner, H J ^a   Kirchner, H ^a   Kluter H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

CD21; Epstein Barr virus; Epstein Barr virus receptors; HLA DR; Resistance

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; VIRUS RECEPTOR;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE FREQUENCY; HERPESVIRUS 4, HUMAN; HLA-DR1 ANTIGEN; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, COMPLEMENT 3D;

EID: 0032998522     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00912.x     Document Type: Article

References (26)

1. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989; 46:183-219.
2. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Bird PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor, CR2. Proc Natl Acad Sci USA 1984; 81:4510-4.
3. Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W. Epstein Barr virus/complement C3d receptor is an interferon α receptor. EMBO J 1991; 10:919-26.
4. Tsoukas CD, Lambris JD. Expression of EBV/C3d receptors on T cells: biological significance. Immunol Today 1993; 14:56-59.
5. Birkenbach M, Tong X, Bradbury LE, Tedder TF, Kieff E. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med 1992; 176:1405-14.
6. Bonnefoy JY, Pochon S, Aubry JP, Graber P, Gauchat JF, Jansen K, Flores-Romo L. A new pair of surface molecules involved in human IgE regulation. Immunol Today 1993; 14:1-2.
7. Tanner J, Weiss J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates absorption, capping, and endocytosis. Cell 1987; 50:203-13.
8. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, ed. Virology. New York: Raven Press, 1995:2397-446.
9. de-Thé G, Day NE, Geser A et al. Seroepidemiology of the Epstein-Barr virus: preliminary analysis of an international study - A review. In: De-Thé G, Epstein MA, zur Hausen H, eds. Oncogenesis and herpes viruses II. Lyon: IARC Scientific Publication, 1975; 11:3-18.
10. Schmader KE, van der Horst CM, Klotman ME. Epstein-Barr virus and the elderly host. Rev Infect Dis 1989; 11:64-73.
11. Jabs WJ, Wagner HJ, Neuslock P, Klüter H, Kirchner H. Immunologic properties of Epstein-Barr virus-seronegative adults. J Infect Dis 1996; 173:1248-51.
12. Gervais F, Willis A, Leyritz M, Lebrun A, Joncas JH. Relative lack of Epstein Barr virus (EBV) receptors on B cells from persistently EBV seronegative adults. J Immunol 1981; 126:897-900.
13. Li Q, Springs MK, Kovats S, Turk SM, Comeau MR, Nepom B, Hutt-Fletcher LM. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 1997; 71:4657-62.
14. Bein G, Gläser R, Kirchner H. Rapid HLA-DRBI genotyping by nested PCR amplification. Tissue Antigens 1992; 39:68-73.
15. Cohen JHM, Fischer E, Kazatchkine MD, Brochier J, Revillard JP. Characterisation of monoclonal antihuman-B-cell antibody BL13 as an anti-C3d-receptor (CR2) antibody. Scand J Immunol 1986; 23:279-85.
16. Klüter H, Schlenke P, Müller-Steinhardt M, Paulsen M, Kirchner H. Impact of buffy coat storage on the generation of inflammatory cytokines and platelet activation. Transfusion 1997; 37:362-7.
17. Fay SP, Posner RG, Swann WN, Sklar LA. Real-time analysis of the assembly of ligand, receptor, and G protein by quantitative fluorescence flow cytometry. Biochem 1991, 30:5066-75.
18. Ginaldi L, Farahat N, Matutes E, De Martinis M, Morilla R, Catovsky D. Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry. J Clin Pathol 1996; 49:539-44.
19. Denny TN, Stein D, Mui T, Scolpino A, Holland B. Quantitative determination of surface antibody binding capacities of immune subsets present in peripheral blood of healthy blood donors. Cytometry 1996; 26:265-74.
20. Ginaldi L, De Martinis M, D'Ostilio A, Di Gennaro A, Marini L, Quaglino D. Altered lymphocyte antigen expressions in HIV infection. A study by quantitative flow cytometry. Am J Clin Pathol 1997; 108:585-92.
21. Reil A, Bein G, Machulla HKG, Sternberg B, Seyfarth M. High-resolution DNA typing in immunoglobulin A deficiency confirms a positive association with DRB1*0301, DQB1*02 haplotypes. Tissue Antigens 1997; 50:501-6.
22. Illges H, Braun M, Peter HH, Melchers I. Analysis of the human CD21 transcription unit reveals differential splicing of exon 11 in mature transcripts and excludes alternative splicing as the mechanism causing solubilization of CD21. Mol Immunol 1997; 34:683-93.
23. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
24. Spriggs MK, Armitage RJ, Comeau MR et al. The extracellular domain of the Epstein Barr virus BZLF2 protein binds the HLA-DR β chain and inhibits antigen presentation. J Virol 1996; 70:5557-63.
25. Edmond E, Steel CM, Ennis M, Cameron F, Dick H. HLA antigens in adults negative for antibody to Epstein-Barr virus (EBV). Tissue Antigens 1981; 18:252-7.
26. Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol 1998; 72:158-63.